Discovery of 4-((1-(1<em>H</em>-imidazol-2-yl)alkoxy)methyl)pyridines as a new class of <em>Trypanosoma cruzi </em>growth inhibitors (Publications)
The identification of a new series of growth inhibitors of Trypanosoma cruzi, the causative agent of Chagas' disease, is described. In vitro screening of a subset of compounds from our in-house compou
The fight against lymphatic filariasis: perceptions of community drug distributors during mass drug administration in coastal Kenya (Publications)
BACKGROUND: Lymphatic filariasis (LF), a neglected tropical disease (NTD) and leading cause of global disability, is endemic in 32 countries in Africa with almost 350 million people requiring regular
Dual plasmepsin-targeting antimalarial agents disrupt multiple stages of the malaria parasite life cycle (Publications)
Artemisin combination therapy (ACT) is the main treatment option for malaria, which is caused by the intracellular parasite Plasmodium. However, increased resistance to ACT highlights the importance o
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like <em>Mycobacterium tuberculosis</em> (Publications)
TNF-alpha- as well as non-TNF-alpha-targeting biologics are prescribed to treat a variety of immune-mediated inflammatory disorders. The well-documented risk of tuberculosis progression associated wit